Joy Wortham
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1366732398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,694 and has fallen 98.7% since, to $36 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TX, where the typical reported total is $2,974.
Across 168 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$638
- Recordati_rare_diseases_inc.$230
- EUSA Pharma (US) LLC$230
- Mannkind Corporation$230
- Medtronic$175
- Dexcom, Inc.$173
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,135100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $638 |
| Recordati_rare_diseases_inc. | 4 | $230 |
| EUSA Pharma (US) LLC | 4 | $230 |
| Mannkind Corporation | 9 | $230 |
| Medtronic | 9 | $175 |
| Dexcom, Inc. | 6 | $173 |
| AbbVie | 11 | $172 |
| Amneal Pharmaceuticals LLC | 6 | $149 |
| Zealand Pharma US, Inc. | 6 | $127 |
| Abbott | 6 | $125 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Insulet Corporation | 4 | $69 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Lilly USA, LLC | 4 | $64 |
| GRT US Holding, Inc. | 4 | $63 |
| AstraZeneca | 4 | $61 |
| Cequr Corporation | 1 | $59 |
| Boehringer Ingelheim | 3 | $59 |
| Johnson & Johnson | 3 | $52 |
| Bayer | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $36 |
| IBSA Pharma Inc. | 2 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Amgen | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Pfizer | 1 | $12 |
| Althera Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIGNIFOR LAR$170
- ISTURISA$170
- Sylvant$170
How this compares
$3,135 in reported general payments places this provider in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in San Antonio
- Ralph DefronzoSan Antonio$880K
- Firas AkhrassSan Antonio$801K
- Carolina Solis-HerreraSan Antonio$600K
- Jeannie BaqueroSan Antonio$573K
- Kathleen HandsSan Antonio$223K
- Shahid AzizSan Antonio$173K
- William TrigosoSan Antonio$170K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.